K4 Elite logo K4 Elite
Home / Peptide Library / GLOW Blend (BPC-157 · TB-500 · GHK-Cu)
Emerging Research

GLOW Blend (BPC-157 · TB-500 · GHK-Cu)

Skin, Hair & Beauty · ['GLOW', 'BPC-157 / TB-500 / GHK-Cu blend', 'GLOW peptide blend']

A research blend combining three individually studied peptides — BPC-157, TB-500 (thymosin beta-4 fragment), and the copper tripeptide GHK-Cu — investigated in the preclinical literature for tissue repair, angiogenesis, and skin remodeling pathways. Marketed as a fixed combination; no single PubChem identifier exists for the blend.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Research Level
Emerging Research
Available in our store →
🧬

GLOW is a research blend that co-formulates three peptides that have each been studied separately in the laboratory literature: BPC-157 (a synthetic pentadecapeptide derived from a gastric protein sequence), TB-500 (a synthetic fragment corresponding to the actin-binding region of thymosin beta-4), and GHK-Cu (the copper-bound tripeptide glycyl-L-histidyl-L-lysine). Because GLOW is a mixture rather than a single molecule, it has no unique chemical formula, molecular weight, or PubChem CID; each component carries its own identifiers.

The blend is positioned within the "skin, hair and beauty" research space because the three constituents have been examined in preclinical models of wound healing, angiogenesis, extracellular-matrix remodeling, and dermal collagen synthesis. The combination itself has not been the subject of controlled clinical trials, so any characterization of GLOW rests on the separate literature for its individual peptides.

All information here is provided for laboratory and educational reference only. This material describes published research on the component peptides and is not a description of a product intended for human or veterinary use.

The three components are reported to act through distinct pathways in preclinical systems. BPC-157 has been associated in animal studies with modulation of the nitric-oxide system, upregulation of growth-factor receptors such as VEGFR2, and promotion of angiogenesis and fibroblast activity during tissue repair. TB-500, as a thymosin beta-4 fragment, is described in the literature as sequestering G-actin and influencing cell migration, angiogenesis and matrix remodeling.

GHK-Cu is documented as a copper-delivery tripeptide that, in cell-culture and animal models, has been reported to influence expression of genes related to collagen and glycosaminoglycan synthesis, antioxidant defenses, and wound-associated remodeling. The blend is presented as combining these separate mechanisms; no study has demonstrated a unique combined mechanism for the mixture itself.

  • Angiogenesis pathways — BPC-157 has been examined in rodent models for effects on blood-vessel formation and VEGFR2 signaling during tissue repair (Seiwerth et al., 2018).
  • Thymosin beta-4 biology — the parent molecule of TB-500 has been reviewed for roles in actin regulation, cell migration and dermal wound repair (Goldstein et al., 2005).
  • Copper-peptide skin remodeling — GHK-Cu has been studied in vitro for modulation of collagen and matrix gene expression relevant to skin (Pickart & Margolina, 2018).
  • Wound-healing models — the component peptides have each appeared in preclinical wound-closure and granulation-tissue studies.
  • Extracellular-matrix turnover — GHK and thymosin beta-4 fragments have been investigated for effects on fibroblast behavior and matrix protein synthesis.
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Because GLOW is a marketed blend rather than a defined study article, no peer-reviewed protocol describes the mixture. The following are published studies of the individual constituents, reported here for reference only. Seiwerth et al. (2018) reviewed rodent experiments in which BPC-157 was administered in wound and vascular-injury models and reported effects on angiogenesis markers. Goldstein et al. (2005) summarized thymosin beta-4 experiments, including topical and injected animal wound-healing paradigms. Pickart & Margolina (2018) compiled in-vitro and animal data on GHK and GHK-Cu describing gene-expression changes associated with tissue remodeling.

These summaries describe what investigators did in laboratory settings and are not instructions or recommendations. Doses and routes reported in animal studies are property of those studies and are not offered here as guidance.

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

BPC-157 (component)Synergistic
Core repair-oriented constituent of the blend; studied separately for angiogenesis and healing pathways.
TB-500 (component)Synergistic
Thymosin beta-4 fragment component; investigated for cell migration and matrix remodeling in preclinical work.
GHK-Cu (component)Synergistic
Copper tripeptide component contributing the skin-remodeling arm of the blend in the research rationale.
KPVCompatible
An anti-inflammatory tripeptide studied separately; appears together with these peptides in the related KLOW blend.
Vitamin C (ascorbate)Caution
Copper-peptide chemistry can be affected by strong reducing or chelating agents in vitro; relevant when designing laboratory formulations.
  1. Seiwerth et al., BPC 157 and blood vessels (2018), Curr Pharm Des
  2. Goldstein et al., Thymosin beta4 in wound repair (2005)
  3. Pickart & Margolina, Regenerative and protective actions of the GHK-Cu peptide (2018), Int J Mol Sci
  4. Sikiric et al., Stable gastric pentadecapeptide BPC 157 review (2011), Curr Pharm Des
Is GLOW a single molecule?
No. It is a blend of three separate peptides (BPC-157, TB-500, GHK-Cu), so it has no single chemical formula, molecular weight, or PubChem identifier.
Has the GLOW blend itself been clinically tested?
No controlled clinical trials of the combined blend appear in the literature. Available evidence relates to each component peptide studied individually, largely in preclinical models.
What research areas are associated with the components?
Angiogenesis, wound healing, extracellular-matrix remodeling, and dermal collagen biology are the main themes in the separate literature for BPC-157, TB-500 and GHK-Cu.
Why is it grouped under skin, hair and beauty?
Because GHK-Cu and thymosin beta-4 fragments have been studied for skin and matrix remodeling, and the blend is marketed within that research theme.
Can this be used as a supplement or treatment?
No. This entry is for research and educational reference only. It is not a description of a product for human or veterinary use and contains no dosing or administration guidance.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.